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Abstract
Introduction: Mortality rates within the first year of combination antiretroviral therapy (cART) initiation are several-fold
higher in resource-limited countries than in resource-replete settings. However studies in western countries examining
virologic, immunologic and clinical responses after cART initiation in indigenous versus non-indigenous populations have
shown mixed results. This study aimed to determine whether there is a difference in these outcomes in a United States
setting between foreign-born and US-born patients.
Methods: This retrospective observational cohort study of HIV-1 infected adults in one urban clinic in the United States
compared virologic suppression, immune recovery and rates of AIDS defining events (ADEs) within the first year of cART
using linear mixed effect models, log rank tests and Cox proportional hazard models. Data were analyzed for 94 foreign-
born and 1242 US-born patients.
Results: Foreign-born patients were younger (31.7 years versus 38.5 years), more often female (38.3% versus 27.1%), less
often injection drug users (3.2% versus 9.5%) or men who have sex with men (19.0% versus 54.5%), and had higher loss to
follow-up rates (14.9% versus 6.2%). No significant differences were detected between the groups in suppression of plasma
HIV-1 RNA, CD4+ cell recovery or development of ADEs.
Conclusions: During the first year on cART, virologic suppression, immune recovery and development of ADEs were
comparable between foreign-born and US-born patients in care in a US clinic. Differential rates of loss to follow-up warrant
further investigation in the foreign-born population.
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Introduction
Patient outcomes in HIV-infected adults initiating combination
antiretroviral therapy (cART) have been shown to vary depending
on setting. Notably, high rates of early mortality in the months
after cART have been reported from several cohorts in resource
limited countries, with early mortality rates several fold higher in
lower-income countries than in high-income countries.[1–5]
When examining different populations in the same setting, studies
comparing virologic and immunologic outcomes have shown
mixed results. Cohort studies from the United Kingdom and the
Netherlands demonstrated poorer virologic response and higher
rates of disease progression in non-indigenous patients receiving
care in those countries. [6–8] However, analyses from Swiss and
Spanish cohorts showed no such differences between native and
non-native populations. [9,10].
In the United States, foreign-born individuals make up
approximately 13% of the population and accounted for
approximately 16% of the HIV diagnoses between 2007 to
2010. [11] Results of epidemiologic studies from the US have also
been mixed, with one finding that foreign-born patients were more
likely to have AIDS at diagnosis while another showed no
difference in concurrent HIV/AIDS diagnosis compared to US-
born patients. [12,13] No studies have compared outcomes of
foreign-born versus US born patients on antiretroviral treatment.
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52336The aim of this study was to determine whether there was
a difference in virologic, immunologic and clinical outcomes
within one year of cART initiation between foreign-born and US-
born HIV-1 infected adults receiving care in one urban outpatient
HIV clinic in the United States. We hypothesized that patients
from resource-limited regions of the world would experience
poorer virologic suppression and immunologic recovery and would
have higher rates of AIDS-defining events (ADEs).
Methods
We performed a retrospective cohort study among persons in
care at the Comprehensive Care Clinic, a Vanderbilt University-
affiliated public outpatient HIV clinic in Nashville, Tennessee,
USA. The Comprehensive Care Clinic accepts patients regardless
of nationality, insurance status or immigration status, with more
than 80% of the clinic patients utilizing services funded by the
Ryan White Program, a government assistance program for HIV/
AIDS care. The study population included all previously ART-
naive patients initiating cART between January 1, 1998 and
December 31, 2007 whose information had been compiled on
a de-identified dataset. To estimate the association between
birthplace and viral load suppression and CD4+ cell recovery,
a repeated measures analysis was performed on the data using
a linear mixed-effects model adjusted for sex, age and baseline
CD4+ cell count, creating best fit curves of estimated expected
CD4+ cell counts and plasma HIV-1 RNA levels. Time since
cART initiation was included in the model using natural splines
with three knots. Because the limits of detection for HIV-1 RNA
assays changed over time (from ,400 copies/ml to ,48 copies/
ml), we used multiple imputation to assign HIV-1 RNA values of
,400 to be from 49 to 399 copies/mL; values ,48 were assigned
to be 49 copies/mL. The proportion of patients with suppressed
viral load was estimated using the distribution of the predicted
values of the linear mixed-effects model. Kaplan-Meier estimates
were used to calculate hazard rates of death or developing an ADE
during the year following cART initiation. A log rank test assessed
for differences in rates by birthplace, and Cox proportional hazard
models assessed the relationship between time to death or time to
ADE and baseline variables. Missing values of baseline predictors
were accounted for using single imputation techniques. Country of
origin was determined by patient self-report. Patients without
documented country of origin (n=12) were assumed to be from
the United States. Foreign-born patients from resource-replete
settings (n=2) were excluded. Patients were deemed lost to follow-
up if they had less than one year of follow-up and were not
reported as dead within one year of starting cART. Combined
antiretroviral therapy was defined as (1) at least two nucleoside
reverse-transcriptase inhibitors (NRTIs) in combination with at
least one protease inhibitor (PI) and/or non-NRTI (NNRTI); (2)
one NRTI and any PI and any NNRTI; or (3) at least 3 NRTIs. R
software 2.15.1 (R Foundation for Statistical Computing, Vienna,
Austria, available at: http://www.r-project.org) was used for all
data analyses.
All patients consented to have their data stored in the clinic’s
electronic medical database. The database was stripped of all
protected health information before its use in research. Because we
used this existing de-identified data set, the Vanderbilt University
Institutional Review Board deemed the research exempt from
review.
Results and Discussion
1336 patients met inclusion criteria, consisting of 94 foreign-
born and 1242 US-born patients (Table 1). Forty-nine of the 94
foreign-born patients (52.1%) were from Latin America, with
Mexico the most common country of origin (35/94; 37.2%). A
number of baseline characteristics were significantly different
between foreign-born and US-born groups including age at cART
initiation (median of 31.7 versus 38.5 years, respectively), female
sex (38.3% versus 27.1%) and HIV risk factor, with foreign-born
patients less likely to have had exposure via injection drug use
(3.2% versus 9.5%, respectively) or male to male sexual contact
(19.0% versus 54.5%, respectively). Foreign-born patients were
more likely to be lost-to-follow-up during the first year (14.9%
versus 6.2% in US-born).
Plasma viral load suppression and CD4+ cell recovery remained
comparable in the two groups throughout the year (Figures 1 and
2), with overlapping confidence intervals in both the plasma HIV-
1 RNA level and CD4+ cell count curves. At 90 days, 70.4% of
foreign-born and 64.8% of US born patients had suppressed viral
loads (plasma HIV-1 RNA ,400 copies/ml). Estimated expected
plasma HIV-1 RNA levels were 137 copies/ml (95% CI: 86–220)
and 188 copies/ml (95% CI: 162–218) in foreign-born and US-
born patients respectively while expected CD4+ cell counts were
312 cells/ul (95% CI: 288–336) and 314 cells/ul (95% CI: 307–
322). At 360 days, 57.2% of foreign-born and 53.8% of US born
patients had suppressed viral loads. Estimated expected HIV-1
RNA levels in foreign-born and US-born patients were 278
copies/ml (95% CI: 128–602) and 330 copies/ml (95% CI: 261–
418), respectively, with CD4+ cell counts of 381 cells/ul (95% CI:
331–434) and 360 cells/ul (95% CI: 345–376). Rates of AIDS-
defining events (ADE)s were similar in the two groups, with 11
foreign-born patients (11.7%) versus 152 US-born patients (12.2%)
developing ADEs within the first year following cART initiation
(aHR 1.04; 95% CI: 0.57–1.93). One year crude mortality rates
were 1.2% and 4.7% in foreign-born and US-born patients
respectively (aHR 0.26; 95%CI 0.04–1.87).
Those who were lost to follow-up were younger (35.2 vs. 38
years) and had slightly lower body mass index and CD4+ cell
counts than those who were not lost (data not shown). To further
characterize those lost to follow-up, we compared baseline
attributes of the lost to follow-up group to patients who were
alive and to patients who had died at the end of follow-up to
determine which differences were statistically significant. Com-
pared to the alive group, those lost to follow-up had a lower body
mass index (23 versus 24.5 kg/m
2, p=0.02). Compared to the
dead group, patients lost to follow-up were younger at cART
initiation (35.2 versus 40.7 years, p,0.01), had higher CD4+ cell
counts (median 168 versus 95 cells/ul, p,0.01) and higher
hemoglobin levels (median 13.1 versus 11.3 g/dl, p,0.01). These
differences, though statistically significant, may or may not be
clinically significant.
Contrary to our hypothesis, virologic suppression and CD4+
cell count recovery were similar between foreign-born and US-
born patients during the first year on cART. Likewise, foreign-
born patients did not appear more likely to develop ADEs.
Limitations of our study include the relatively small sample size
and higher lost-to-follow-up rates in the foreign-born group, which
could have affected our ADE results; this along with the low death
rates, limits the reliability of the crude mortality analysis. We
believe our analyses of plasma HIV-1 RNA level and CD4+ cell
count were less affected by loss-to-follow-up because similar
percentages of patients in both groups had viral load and CD4+
cell count data recorded at defined intervals during the year (data
not shown). There were variables related to the patients’ HIV
infection that were not available to the investigators, but may
potentially have an effect on outcomes, such as country of HIV
acquisition, HIV subtype and duration of infection. In addition,
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PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52336our data are from a single urban US site, so our findings may not
be generalizable to other resource-replete settings.
Our cohort had a lower proportion of HIV in foreign-born
individuals than the national average. This is likely due to the
population distribution of foreign-born persons in the United
States. Prosser et al noted the variations that exist in the
distribution of foreign-born persons and patterns of infection at
the state and regional levels. [11].
Conclusions
The present study detected no significant differences in virologic
suppression, CD4+ cell recovery or development of ADEs in the
year after starting cART between foreign-born and US-born HIV-
1 infected patients receiving care in one urban US setting. Given
the higher loss to follow-up rates among foreign-born patients,
a focus on identifying and addressing barriers to retention in care
is warranted.
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Figure 1. Viral load by time on combined antiretroviral
therapy. Adjusted for sex, age and baseline CD4+ cell count.
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Figure 2. CD4+ cell count by time on combined antiretroviral
therapy. Adjusted for sex, age and baseline CD4+ cell count.
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